| October 1 |
Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien Study |
| October 1 |
Critical Pharmaceuticals Enter Sustained Release hGH Arena |
| October 1 |
ImmunoVaccine Technologies' DepoVax Shows Positive Results for Cancer and Infectious Diseases |
| October 1 |
Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology |
| October 1 |
Dicerna Pharmaceuticals Announces Preclinical Findings Highlighting Novel Approach to Maximizing Dicer-Substrate Small Interfering RNAs (DsiRNAs) in Rheumatoid Arthritis; Data Appear Published by Molecular Therapy |
| October 1 |
Watson Announces Positive Data for RAPAFLO(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences |
| October 1 |
Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma |
| October 1 |
Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer |
| October 1 |
Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI) |
| October 1 |
A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV |
| October 2 |
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society |
| October 2 |
Access Pharmaceuticals Presents New Data on the Company's Angiolix Therapeutic Monoclonal Antibody |
| October 2 |
Journal: Scientists Identify Successful 'Anti' Antibiotic That May Help Curb Rising Staph Infections |
| October 2 |
Provectus Lead Investigator Professor John F. Thompson Presents at “Perspectives in Melanoma XII” Conference |
| October 3 |
Pharmaxis Research Programs Highlighted at European Respiratory Society Congress |
| October 3 |
New Publication Shows Cleviprex Provides More Precise Blood Pressure Control in Cardiac Surgery Patients |
| October 3 |
New Chemotherapy ‘Cures’ Early Testicular Cancer |
| October 3 |
MaxCyte to Present at AABB Annual Meeting & TXPO 2008 in Montreal, Quebec, Canada |
| October 6 |
New Findings Show Efficacy of Remicade Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study |
| October 6 |
CombinatorX Announces Top-Line Results from Phase 2b Study of Synavive (CRx-102) for Knee Osteoarthritis |
| October 6 |
COPD Landmark UPLIFT trial proves tiotropium significantly reduces risk of death, improves quality of life, sustains lung function improvements over four years |
| October 6 |
Genta Updates Progress of its Phase 3 Trial of Genasense in Patients with Advanced Melanoma AGENDA Trial Expected to Complete Accrual Early 2009 |
| October 6 |
Orexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave |
| October 6 |
Dendreon Announces Interim Data from Phase 3 Provenge IMPACT Trial |
| October 6 |
Dendreon Announces Interim Data From Phase 3 Provenge IMPACT Trial |
| October 6 |
Shire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA (mesalamine) and Asacol (mesalamine) for the Treatment of Ulcerative Colitis (UC) at the American College of Gastroenterology (ACG) Meeting |
| October 6 |
Cortex's Ampakine Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany |
| October 6 |
Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting |
| October 6 |
Cimzia (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients |
| October 6 |
Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS) |
| October 6 |
Bayer Reports Progress in Clinical Program for Riociguat |
| October 6 |
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer |
| October 6 |
Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Phase 2 Study |
| October 6 |
Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS) |
| October 6 |
Video: COPD Landmark Trial UPLIFT Proves Tiotropium Sustains Lung Function Improvements Over Four Years and Improves Survival Rate |
| October 6 |
Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed |
| October 6 |
VIVUS Announces the Weight Loss Effects of Qnexa in Type 2 Diabetes |
| October 6 |
Cortex’s AMPAKINE Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany |
| October 7 |
New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium |
| October 7 |
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine |
| October 7 |
Bavarian Nordic announces positive mature Phase II results from newly acquired prostate cancer vaccine |
| October 7 |
NVA237 Phase II results presented at the European Respiratory Society Annual Meeting show promising efficacy and tolerability with potentially faster onset than tiotropium |
| October 7 |
Data Show Aerovance's Aerovant Inhalation Powder is Well Tolerated in Asthma Patients |
| October 7 |
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium |
| October 7 |
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation |
| October 7 |
Cimzia (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients |
| October 7 |
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting |
| October 7 |
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop |
| October 7 |
Media Advisory: New Amitiza (lubiprostone) and Irritable Bowel Syndrome with Constipation Data Presented at the American College of Gastroenterology 2008 Annual Meeting Expands Breadth and Depth of State of the Science |
| October 7 |
Orexigen Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates |
| October 7 |
Study Published in Journal of Clinical Psychiatry Showed Once-Daily Vyvanse (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD |
| October 7 |
Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds |
| October 7 |
Pivotal Phase III study shows MabThera delays disease progression in patients with relapsed or refractory Chronic Lymphocytic Leukaemia |
| October 7 |
Study Shows EUFLEXXA Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period |
| October 7 |
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting |
| October 7 |
Biovest Announces BiovaxID Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44% |
| October 7 |
Advaxis Incorporated Collaborates on Groundbreaking Listeria Moncoytogenes Immunotherapy Research Discovery |
| October 8 |
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease |
| October 8 |
Vical Expands Applications of Vaxfectin Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months |
| October 8 |
LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease |
| October 8 |
Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress |
| October 8 |
Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority of Fibrin Pad Versus SURGICEL in Mild to Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials |
| October 8 |
NovaBay Pharmaceuticals To Present Data On Lead Anti-Infective Compound at First-Ever ICAAC/IDSA Joint Meeting |
| October 8 |
Use Of Medication For Enlarged Prostate Not Associated With Increased Risk Of Hip Fracture |
| October 8 |
Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference |
| October 8 |
Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference |
| October 8 |
Health Discovery Corporation's New Prostate Cancer Test is Ready for Commercialization Following Successful Completion of Final Clinical Trials |
| October 8 |
One Year of GATTEX Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome |
| October 8 |
Protox Announces Positive 12 Month Data from BPH Study |
| October 8 |
Viral Genetics, Inc. Invited to Present New Model, Initial Findings of Lyme Disease Study at Prestigious ILADS Conference |
| October 9 |
Diamyd Study Published in Prestigious New England Journal of Medicine |
| October 9 |
Paper in Cell Cycle Reports Alfacell's ONCONASE Targets siRNA |
| October 9 |
Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at the 15th International Symposium on Hepatitis C Virus and Related Viruses |
| October 9 |
MIV Therapeutics Announces Participation at TCT 2008 in Washington, D.C. |
| October 9 |
Clinical Data from 'OPEN I' Study of the Stentys Stent to Be Reported at Next Week's 'TCT 2008' International Cardiovascular Meeting |
| October 10 |
Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis |
| October 10 |
Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of Taxus Coronary Stent Systems at TCT 2008 |
| October 10 |
Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times |
| October 10 |
The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008 |
| October 13 |
GTx Announces Investigational Ostarine (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial |
| October 13 |
Archimedes Pharma Announces First Positive Phase III Clinical Trial Results for NasalFent |
| October 13 |
Peregrine Pharmaceuticals' anti-PS Technology Platform to Be Discussed at AIDS Vaccine 2008 Conference |
| October 13 |
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results |
| October 13 |
Kamada Reports Positive Phase II Data with Inhaled AAT in Cystic Fibrosis |
| October 13 |
Avontec announces the results of a successful proof of concept within a phase 2a study with its drug candidate AVT-02 UE ointment after topical treatment in patients with mild-to-moderate psoriasis |
| October 13 |
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels |
| October 13 |
SUVN-502 data being presented at 16th BioPartnering in London |
| October 13 |
Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream |
| October 13 |
Acura Pharmaceuticals And King Pharmaceuticals Announce Positive Top Line Results Of Key Clinical Study Assessing Abuse Liability |
| October 13 |
Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 |
| October 13 |
TAXUS Express Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program |
| October 13 |
New Data on Medtronic's ENDEAVOR Drug-Eluting Coronary Stent Shows Strong Performance in Complex Patients and Durable Efficacy |
| October 13 |
First Heart Failure Patients Successfully Implanted with Angioblast Systems' "Off-the-Shelf" Adult Stem Cells |
| October 13 |
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania Stent in Treatment of De Novo Coronary Lesions |
| October 13 |
Medtronic's Third-Generation Endeavor Resolute Drug-Eluting Stent Maintains Strong Efficacy and Safety Profile at Two Years |
| October 13 |
Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent |
| October 13 |
XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week |
| October 13 |
Medtronic Announces Plans to Release Data on Broad Portfolio of Cardiovascular Innovations at TCT 2008 |
| October 13 |
Abbott's XIENCE V Drug Eluting Stent Outperforms TAXUS in Key Efficacy and Safety Endpoints Out to Two Years |
| October 13 |
Fast Treatment Can Reverse Progress of Newly Recognized Disease Anti-NMDA Receptor Encephalitis and its Related Tumor |
| October 14 |
Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease |
| October 14 |
Aradigm Completes Enrollment in Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Bronchiectasis |
| October 14 |
HemCon Medical Technologies, Inc. Announces Promising Results from Nail Anti-Fungal Study |
| October 14 |
Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy |
| October 14 |
Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous Bio-engineered R stent |
| October 14 |
Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference |
| October 14 |
Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease |
| October 14 |
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure |
| October 14 |
Long-Term Follow-Up Data Confirm Cox-2 Inhibitor Rofecoxib Substantially Increases Risk of Stroke, Heart Attack, And Death |
| October 14 |
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol |
| October 14 |
Nu Skin Scientists Correlate the Appearance of Aging With arNOX Free Radical Generator |
| October 14 |
Provectus Announces First Peer-Reviewed Publication on PV-10 in "Melanoma Research" |
| October 14 |
The Medicines Company Announces HORIZONS-AMI 1-Year Data To Be Presented at 2008 TCT Meeting |
| October 14 |
VaxInnate to Present Positive Results from Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/IDSA Meeting |
| October 14 |
Sustained Safety Profile of Medtronic's Endeavor Drug-Eluting Stent Differentiates It from Other DES |
| October 14 |
ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium |
| October 14 |
Endeavor Vs. Taxus: Medtronic's Drug-Eluting Coronary Stent Linked to Fewer Heart Attacks at Two Years Post Implant |
| October 14 |
SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS Express2 Stents and Bypass Surgery |
| October 15 |
Lexicon to Present Clinical Data for LX2931, an Investigational New Drug for Rheumatoid Arthritis |
| October 15 |
Phase 1 Clinical Trial Results of Anti-MRSA Drug Presented at ICAAC/IDSA |
| October 15 |
New Class of Drug Candidates Developed by Santaris Pharma Can Potently Counteract Disease-Associated MicroRNAs |
| October 15 |
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated with Second-Generation TAXUS Liberte Stent |
| October 15 |
Geron's GRN163L Sensitizes Resistant Breast Cancer Cells to Trastuzumab in Preclinical Study |
| October 15 |
VGX Pharmaceuticals Presents Non-Human Primate Study Data at AIDS Vaccine 2008 Conference |
| October 15 |
HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS Drug-Eluting Stents in Heart Attack Patients |
| October 15 |
Angiomax Reduced Cardiac Mortality by 43 Percent and Improved Overall Survival by 31 Percent at One-Year in HORIZONS-AMI Trial |
| October 15 |
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus |
| October 15 |
Savient to Host Conference Call on Pegloticase Scientific Presentations |
| October 15 |
University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding |
| October 15 |
Angiomax_ Reduced Cardiac Mortality By 43 Percent And Improved Overall Survival By 31 Percent In Horizons/AMI Trial |
| October 16 |
Idera Pharmaceuticals Presents Data from Autoimmune Disease Program at 4th Annual Meeting of the Oligonucleotide Therapeutics Society |
| October 16 |
EPIX Pharmaceuticals to Present at the Alzheimer's Association Research Roundtable Meeting |
| October 16 |
GTx Announces Presentation of Toremifene 80 mg Data at Fourth Annual Chicago Supportive Oncology Conference |
| October 16 |
Alnylam Scientists Present Data from Multiple Programs at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society |
| October 16 |
Tranzyme Pharma's Ghrelin Agonist TZP-101 Shows Potential as a Potent Agent for Cancer Cachexia |
| October 16 |
Exelixis Submits Diligence Report for Cdc7 Inhibitor to Bristol-Myers Squibb |
| October 16 |
BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease |
| October 16 |
SDI Reports: Patients in the Midwest Taking Anti-Seizure Medications Prescribed by a Neurologist Maintain Therapy 16% Longer Than the National Average |
| October 16 |
NPS Pharmaceuticals Announces Multiple GATTEX Data Presentations at 16th United European Gastroenterology Week Meeting |
| October 16 |
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin’s Lymphoma |
| October 16 |
Cytopia Scientific Presentations on JAK2 Inhibitor Program |
| October 16 |
Obagi Medical Products' ELASTIderm Decolletage System Reduces Visible Signs of Aging on Chest and Neck |
| October 16 |
GeoVax Presents Data at AIDS Vaccine 2008 Conference |
| October 16 |
NPS Pharmaceuticals Announces Multiple Gattex Data Presentations at 16th United European Gastroenterology Week Meeting |
| October 16 |
Zafgen Inc. to Present at First Annual Boston Biotech R&D Conference |
| October 16 |
Enzon to Present Data at EORTC-NCI-AACR |
| October 16 |
Elixir Medical Corporation Announced Positive First-In-Man Results from Three Drug Eluting Coronary Stent Systems |
| October 16 |
Exelixis Will Have 15 Presentations at the 2008 EORTC-NCI-AACR Annual Meeting |
| October 16 |
Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapies Obatoclax and GMX1777 at the 20th Annual EORTC-NCI-AACR Symposium |
| October 16 |
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma |
| October 16 |
Study in Today's New England Journal of Medicine Suggests Benefits of Genzyme’s Thymoglobulin Sustained Through Five Years in Kidney Transplant Patients |
| October 16 |
ARIAD to Present Data on Deforolimus and AP24534 at 20th Annual EORTC-NCI-AACR Symposium |
| October 16 |
Isotechnika Partner Invited to Present on Drug Eluting Stent Trial Using Voclosporin |
| October 17 |
Positive Phase II Data on Cougar Biotechnology's CB7630 Presented at Prostate Cancer Foundation Scientific Retreat |
| October 17 |
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes |
| October 17 |
Danish Study Supports Efficacy of Endeavor Stent |
| October 17 |
Preliminary Phase I Safety Data for Preventive HIV Vaccine Delivered by Ichor's TriGrid to be Presented at AIDS Conference |
| October 17 |
Telavancin Data to be Presented at Upcoming Scientific Conferences |
| October 20 |
NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics |
| October 20 |
Basilea announces new data to be presented on ceftobiprole and isavuconazole at ICAAC/IDSA |
| October 20 |
Vertex Announces Positive 28-Day Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis |
| October 20 |
MediGene Reports Positive Final Results from EndoTAG-1 Phase II Study in Pancreatic Cancer |
| October 20 |
Acterma (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting |
| October 20 |
Data from Optimer Pharmaceuticals' Prulifloxacin Phase 3 Trial in Traveler's Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting |
| October 20 |
Enzon Presents New Data on Its LNA Programs |
| October 20 |
Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies |
| October 20 |
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy |
| October 20 |
Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics' |
| October 20 |
ONSOLIS (BEMA Fentanyl) Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Meeting |
| October 20 |
Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting |
| October 20 |
TaiGen Announces Presentation of Nemonoxacin at the Joint Meeting of ICAAC/IDSA |
| October 20 |
Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA |
| October 20 |
High-Dose Zevalin With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma |
| October 20 |
Array BioPharma to Present Clinical Data at the 2008 ACR/ARHP Annual Scientific Meeting |
| October 20 |
Statins Reduce Risk of Alzheimer's Disease According to New Long-Term Prospective Study |
| October 21 |
Cyclacel to Present Preclinical Data Showing Synergy of Combination of Sapacitabine with Histone Deacetylating Agents |
| October 21 |
EPIX Pharmaceuticals to Present at the North American Cystic Fibrosis Conference |
| October 21 |
Poor Perioperative Blood Pressure Control Linked to 30-Day Morbidity and Mortality in Cardiac Surgery Patients |
| October 21 |
Avigen Announces AV650 Did Not Meet Efficacy Endpoints in Phase 2b Clinical Trial for Spasticity in Patients With Multiple Sclerosis |
| October 21 |
Sucampo Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation |
| October 21 |
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008 |
| October 21 |
Access Pharmaceuticals Presents ProLindac Data at the AACR-NCI-EORTC Symposium 2008 |
| October 21 |
Peregrine Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer |
| October 21 |
Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study |
| October 21 |
Sunesis Announces Multiple Clinical Data Presentations |
| October 21 |
Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call |
| October 21 |
NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 |
| October 21 |
Aiming at Multiple Alzheimer's Proteins May be Key to Success |
| October 21 |
Argos Therapeutics Publishes Approach to Generating High-Avidity Cytotoxic T Cells with Dendritic Cell-Based Immunotherapy |
| October 22 |
Targanta Therapeutics Releases Results from Phase 2 SIMPLIFI Study Evaluating Single or Infrequent Doses of Oritavancin |
| October 22 |
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients |
| October 22 |
Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium |
| October 22 |
ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Cancer |
| October 22 |
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer |
| October 22 |
Redpoint Bio Researchers Develop Method of Measuring and Classifying Bitterness in a Broad Range of Orally Aversive Pharmaceuticals |
| October 22 |
Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer |
| October 22 |
Nexium (esomeprazole) First PPI to Demonstrate Sustained Reduction in Peptic Ulcer Re-Bleeding in Large Scale Multinational Placebo-Controlled Clinical Study |
| October 22 |
PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008 |
| October 22 |
Independent Study Reveals Synvisc Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Knee Osteoarthritis |
| October 22 |
Clinical Study of Intermezzo for the Treatment of Middle of the Night Awakening Published in SLEEP |
| October 22 |
AdvanDx's PNA FISH Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections |
| October 22 |
Exelixis Reports Positive Phase 1 Data for PI3K Inhibitor XL147 at EORTC-NCI-AACR Symposium |
| October 22 |
Persistent Vaccination Effect of Grazax After Completion of Treatment |
| October 22 |
Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on 'Molecular Targets and Cancer Therapeutics' Demonstrate Superior Profile of S*BIO's Novel Anti-Cancer Drug SB939 |
| October 22 |
ERYtech Pharma Proposes New Anticancer Vaccine Technology |
| October 22 |
Aileron Advances First Stapled Peptide Drug Candidate that Targets Newly-Discovered BAX Activation Mechanism |
| October 22 |
Tekmira Pharmaceuticals Announces Presentation of Data Using SNALP RNAi Delivery Technology |
| October 22 |
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium |
| October 23 |
Opexa Provides Additional Promising Data Including Statistically Significant Reduction in Disability With Tovaxin for the Treatment of Multiple Sclerosis |
| October 23 |
SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy |
| October 23 |
Proteolix Presents Solid Tumor Clinical Trial Results for Carfilzomib at EORTC-NCI-AACR International Conference |
| October 23 |
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist |
| October 23 |
Exelixis Reports Encouraging Phase 1 Data for XL184 at EORTC-NCI-AACR Symposium |
| October 23 |
Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis at the North American Cystic Fibrosis Conference |
| October 23 |
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia |
| October 23 |
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model |
| October 23 |
Auspex Pharmaceuticals Announces Positive Results from Clinical Study of SD-254, A Next-Generation Potential Treatment for Depression |
| October 23 |
Isolagen, Inc. Provides Analysis of Data from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles |
| October 23 |
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis |
| October 23 |
Altus Pharmaceuticals Announces Presentation of Phase 3 Trizytek Efficacy Data at the North American Cystic Fibrosis Conference |
| October 23 |
Cougar Biotechnology Presents Positive CB7630 Phase II Data at EORTC-NCI-AACR Symposium |
| October 23 |
ARIAD Presents Preclinical Data on Deforolimus and Bicalutamide in Androgen-Independent Prostate Cancer |
| October 23 |
ZIOPHARM Presents Darinaparsin Molecular Mechanism of Action and Preliminary Oral Administration Phase I Clinical Data at the EORTC-NCI-AACR Symposium |
| October 23 |
DUSA Announces Results for Phase IIB Trial Of Levulan Photodynamic Therapy for Moderate to Severe Acne |
| October 23 |
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model |
| October 23 |
Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif |
| October 23 |
Report Finds Risks of Developing Alzheimer's and Parkinson's Diseases can be Dramatically Reduced |
| October 23 |
Curis Announces Preclinical Efficacy Data for CUDC-305 at EORTC-NCI-AACR Symposium |
| October 23 |
Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial |
| October 23 |
Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora |
| October 23 |
MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology |
| October 23 |
Exelixis Reports Positive Phase 1 Data for XL228 at EORTC-NCI-AACR Symposium |
| October 23 |
Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference |
| October 23 |
Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer |
| October 23 |
Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time |
| October 23 |
Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting |
| October 24 |
Infinity Pharmaceuticals Announces Preclinical Pancreatic Cancer Data for IPI-926 (Hedgehog Pathway Inhibitor) at EORTC-NCI-AACR Cancer Meeting |
| October 24 |
Inspire Announces New Data from Denufosol Phase 3 Program at North American Cystic Fibrosis Conference |
| October 24 |
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients |
| October 24 |
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs |
| October 24 |
Telmisartan (MICARDIS) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients |
| October 24 |
Key Data Presented for Gemin X Programs at the 20th Annual ENA Symposium |
| October 24 |
Ardea Biosciences Presents Preclinical Data on its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy with Other Anti-Cancer Agents in Multiple Tumor Types |
| October 24 |
Ariad Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors |
| October 24 |
Infinity's Hedgehog Pathway Inhibitor IPI-926 Demonstrates Significant Tumor Growth Inhibition in Human Pancreatic Cancer Model |
| October 24 |
LAB Research's Hungarian site successfully completes GLP certificate i... |
| October 24 |
MedImmune to Present Nine Abstracts on RSV and Influenza at 48th Annual ICAAC/46th Annual IDSA Meeting |
| October 24 |
Oral Fumarate Reduces Disease Activity In Relapsing-Remitting Multiple Sclerosis, And Phase Iii Results Now Awaited |
| October 24 |
Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis |
| October 24 |
Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium |
| October 24 |
Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies |
| October 27 |
Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity |
| October 27 |
Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential for Once Daily Dosing of Novel Oxazolidinone Antibiotic |
| October 27 |
Panacos Presents Phase 2b Bevirimat Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy |
| October 27 |
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting |
| October 27 |
Targanta Presents Efficacy and Safety Data for Oritavancin for the Treatment of Gram-Positive Complicated Skin and Skin Structure Infections (cSSSI) |
| October 27 |
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis |
| October 27 |
Longer-Lasting Restylane Beauty Results Confirmed |
| October 27 |
BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza |
| October 27 |
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy |
| October 27 |
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA |
| October 27 |
Sunesis Announces Updated Clinical Data of Voreloxin in Platinum-Resistant Ovarian Cancer |
| October 27 |
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis |
| October 27 |
Enzon's HIF-1 Alpha Antagonist Shows Antitumor Activity |
| October 27 |
PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results |
| October 27 |
Actemra (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments |
| October 27 |
Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting |
| October 27 |
Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer |
| October 27 |
Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting |
| October 27 |
Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302 |
| October 27 |
XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models |
| October 27 |
CombinatoRx Provides In-Depth Analysis from Phase 2b Knee Osteoarthritis Study of Synavive (CRx-102) with Clinical Investigators |
| October 27 |
MethylGene Presents Preclinical Data for MGD290, a Hos2 Fungal Inhibitor, at Joint ICAAC/IDSA Annual Meeting |
| October 27 |
New Phase III Study in Previously Untreated HIV Patients Showed Merck's Isentress (raltegravir) Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination with Other Medicines |
| October 27 |
Cimzia (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years |
| October 27 |
High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older |
| October 27 |
Statins Show Promise for Blood Clot Prevention |
| October 27 |
Ardea Biosciences Presents Preliminary Data from a Phase 1 Study of RDEA594 at the 2008 ACR/ARHP Annual Scientific Meeting |
| October 27 |
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference |
| October 27 |
Ardea Biosciences Presents Additional Phase 2a and Preclinical Data on its Lead HIV Product Candidate, RDEA806, at the 48th Annual ICAAC/IDSA 46th Annual Meeting |
| October 27 |
Pfizer’s Novel HIV/AIDS Treatment Selzentry (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naïve HIV Patients |
| October 27 |
New Study Supports Use of Levaquin as a Guideline-Concordant Antibiotic for the Treatment of Community-Acquired Pneumonia (CAP) |
| October 27 |
Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen |
| October 27 |
NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy |
| October 27 |
Phase I/II Data Show that GSK’s Altabax (retapamulin ointment), 1% Decolonizes Staphylococcus aureus from Nasal Passages |
| October 27 |
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two |
| October 27 |
Bio-Quant Awarded Full AAALAC Accreditation |
| October 27 |
Enbrel (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis |
| October 27 |
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study |
| October 27 |
"Cancer Research" Journal Publishes Successful Angiogenesis Study Using Optimata's Technology |
| October 27 |
GPC Biotech Presents New Pre-Clinical Data on RGB-286638 Broad-Spectrum Kinase Inhibitor at EORTC-NCI-AACR Meeting |
| October 27 |
New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria |
| October 27 |
Zosano Pharma, Inc. Announces Positive Results of Phase 2 Osteoporosis Study |
| October 27 |
Publication on 'Tregitopes' in Blood Journal of October 2008 |
| October 27 |
Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus |
| October 27 |
Epistem to Present Plucked Hair Biomarker Data at ASCO-NCI-EORTC Meeting |
| October 28 |
Pivotal Phase III Data Confirm The Efficacy And Safety Of Arpida’s Intravenous Iclaprim In Treating Patients With Complicated Skin And Skin Structure Infections |
| October 28 |
QLT Announces Encouraging Phase II Data from Core Study of Punctal Plug Drug Delivery System |
| October 28 |
Basilea presents research data at ICAAC/IDSA on novel antibiotic addressing the emerging threat from multi-resistant Gram-negative bacteria |
| October 28 |
Forest Laboratories Presents Phase III Results on cSSSI at ICAAC |
| October 28 |
GPC Biotech Presents New Pre-Clinical Data on RGB-286638 Broad-Spectrum Kinase Inhibitor at EORTC-NCI-AACR Meeting |
| October 28 |
Galapagos NV (BE) - Nanocort demonstrates safety and good response in Phase I/II trial |
| October 28 |
Geron Scientists and Collaborators Demonstrate Activity of Pancreatic Islet-Like Cells Derived From Human Embryonic Stem Cells in Diabetes |
| October 28 |
Onconova Therapeutics Announces Publication of Positive Phase I Results for Lead Anticancer Compound in Journal of Clinical Oncology |
| October 28 |
Panacos Announces Preliminary Results of Bevirimat Study 204 |
| October 28 |
Nuvo Research Presents Positive Phase III Study Results for Pennsaid at Leading Rheumatology Conference |
| October 28 |
New Phase III Study in Previously Untreated HIV Patients Showed Raltegravir Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination with Other Medicines |
| October 28 |
Nycomed's Daxas Shows Encouraging Preliminary Results in Phase III COPD Studies |
| October 28 |
ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases |
| October 28 |
Nycomed’s Daxas shows encouraging preliminary results in phase III COPD studies |
| October 28 |
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two |
| October 28 |
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim |
| October 28 |
Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible |
| October 28 |
Gemin X Pan Bcl-2 Inhibitor Obatoclax Shows Biological and Clinical Activity in Heavily Pre-Treated Patients with Advanced CLL |
| October 28 |
Argos Therapeutics Publishes Novel Approach to Improving Stimulation of Immunotherapeutic Pathways via Dendritic Cells |
| October 28 |
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim |
| October 28 |
Provectus Announces Completion of Phase 1 Clinical Trial of PV-10 in Recurrent Breast Cancer |
| October 28 |
BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza |
| October 28 |
'Old Blood' Linked To Infection |
| October 28 |
Antiseizure Drug Could be Fatal |
| October 28 |
US Nicotine Addiction Reaches 15-Year High |
| October 28 |
Premier Research Honored as 'Clinical Research Team of the Year' at 2008 GCPj Awards |
| October 28 |
Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections |
| October 28 |
Newly Published Preclinical Study Shows Receptor BioLogix's Pan-HER Ligand Trap Has Broad Anti-Cancer Activity |
| October 28 |
PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results |
| October 28 |
Active Biotech Presents New Data regarding the 57-57 SLE Project at American College of Rheumatology Meeting |
| October 28 |
PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008 |
| October 28 |
Polymedix to Make Multiple Presentations of New Antibiotic Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) |
| October 28 |
Data Demonstrate Orencia (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis |
| October 28 |
Gilead Announces Two-Year Clinical Data for Letairis (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1) |
| October 28 |
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer's Disease Study |
| October 28 |
New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD |
| October 28 |
Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008 |
| October 28 |
Recent Clinical Trial data for Nymox NX-1207 Drug to Be Presented at American Urological Association Meeting in Monterey on Thursday |
| October 28 |
Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco |
| October 28 |
S |
